Display options
Cite
Zhang HN, Xue JB, Wang AZ, et al. EASINESS: . Front Immunol. 2021;12:747267doi: 10.3389/fimmu.2021.747267.
Zhang, H. N., Xue, J. B., Wang, A. Z., Jiang, H. W., Merugu, S. B., Li, D. W., & Tao, S. C. (2021). EASINESS: . Frontiers in immunology, 12747267. https://doi.org/10.3389/fimmu.2021.747267
Zhang, Hai-Nan, et al. "EASINESS: ." Frontiers in immunology vol. 12 (2021): 747267. doi: https://doi.org/10.3389/fimmu.2021.747267
Zhang HN, Xue JB, Wang AZ, Jiang HW, Merugu SB, Li DW, Tao SC. EASINESS: . Front Immunol. 2021 Dec 03;12:747267. doi: 10.3389/fimmu.2021.747267. eCollection 2021. PMID: 34925322; PMCID: PMC8677947.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2021 Dec 03;12:747267. doi: 10.3389/fimmu.2021.747267. eCollection 2021.

EASINESS: .

Frontiers in immunology

Hai-Nan Zhang, Jun-Biao Xue, Aru Ze-Ling Wang, He-Wei Jiang, Siva Bhararth Merugu, Da-Wei Li, Sheng-Ce Tao

Affiliations

  1. Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.
  2. Engineering Research Center of Cell and Therapeutic Antibody of Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.

PMID: 34925322 PMCID: PMC8677947 DOI: 10.3389/fimmu.2021.747267

Abstract

Antibodies are one of the most important groups of biomolecules for both clinical and basic research and have been developed as potential therapeutics. Affinity is the key feature for biological activity and clinical efficacy of an antibody, especially of therapeutic antibodies, and thus antibody affinity improvement is indispensable and still remains challenging. To address this issue, we developed the

Copyright © 2021 Zhang, Xue, Wang, Jiang, Merugu, Li and Tao.

Keywords: 18A4Hu; antibody affinity improvement; directed evolution; error-prone DNA polymerase I; protein-fragment complementation assay

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Nature. 1990 Dec 6;348(6301):552-4 - PubMed
  2. Nat Biotechnol. 2002 Nov;20(11):1129-34 - PubMed
  3. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010 Jan;26(1):49-51 - PubMed
  4. Nat Biotechnol. 2005 Sep;23(9):1147-57 - PubMed
  5. Science. 1988 May 20;240(4855):1038-41 - PubMed
  6. Biochem Biophys Res Commun. 2016 Jun 17;475(1):57-63 - PubMed
  7. Nat Biotechnol. 1997 Jun;15(6):553-7 - PubMed
  8. EMBO J. 1987 Sep;6(9):2781-4 - PubMed
  9. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12141-6 - PubMed
  10. Nature. 2011 Apr 28;472(7344):499-503 - PubMed
  11. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9727-32 - PubMed
  12. Cancer Lett. 2019 May 1;449:125-134 - PubMed
  13. J Mol Biol. 1995 Dec 1;254(3):392-403 - PubMed
  14. Nature. 2020 Aug;584(7819):120-124 - PubMed
  15. Science. 2015 Jan 23;347(6220):1260419 - PubMed
  16. MAbs. 2021 Jan-Dec;13(1):1860476 - PubMed
  17. J Biomed Sci. 2020 Jan 2;27(1):1 - PubMed
  18. Cell. 2018 Dec 13;175(7):1946-1957.e13 - PubMed
  19. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14130-5 - PubMed
  20. Clin Dev Immunol. 2012;2012:980250 - PubMed
  21. Nature. 2018 Aug;560(7717):248-252 - PubMed
  22. Nat Med. 1996 Jan;2(1):100-2 - PubMed
  23. Nat Commun. 2019 Jul 3;10(1):2947 - PubMed
  24. Nat Biotechnol. 2018 Oct;36(9):847-856 - PubMed
  25. Methods Mol Biol. 2012;805:139-61 - PubMed
  26. Science. 2016 Sep 9;353(6304):1147-51 - PubMed
  27. Elife. 2016 May 30;5: - PubMed
  28. Science. 2017 May 26;356(6340): - PubMed
  29. Biochem Biophys Res Commun. 2018 Apr 30;499(1):71-77 - PubMed
  30. Nat Commun. 2018 Oct 8;9(1):4141 - PubMed
  31. Immunol Today. 2000 Aug;21(8):379-82 - PubMed
  32. Prostate. 2013 Feb 15;73(3):306-15 - PubMed
  33. Nat Commun. 2020 Nov 6;11(1):5644 - PubMed
  34. MAbs. 2020 Jan-Dec;12(1):1703531 - PubMed
  35. Science. 2009 Oct 9;326(5950):285-9 - PubMed
  36. Cancer Lett. 2011 May 1;304(1):1-7 - PubMed
  37. Cell. 2018 Jan 11;172(1-2):55-67.e15 - PubMed
  38. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11346-51 - PubMed
  39. Microb Cell Fact. 2016 Mar 02;15:47 - PubMed
  40. Protein Sci. 1998 May;7(5):1214-20 - PubMed
  41. Protein Cell. 2012 Jun;3(6):460-9 - PubMed
  42. J Bacteriol. 1988 Jul;170(7):3040-5 - PubMed
  43. Nat Biotechnol. 2020 Jul;38(7):883-891 - PubMed
  44. Genetics. 2010 Nov;186(3):791-9 - PubMed
  45. Biotechnology (N Y). 1992 Jul;10(7):779-83 - PubMed
  46. Methods Mol Biol. 2013;966:359-66 - PubMed
  47. Cell Host Microbe. 2020 Jun 10;27(6):891-898.e5 - PubMed
  48. Nat Chem Biol. 2021 Oct;17(10):1057-1064 - PubMed
  49. Mol Biotechnol. 2019 Nov;61(11):801-815 - PubMed

Publication Types